Revmoxicam solution for intramuscular injection 15mg/1.5ml in ampoules 1.5ml №5×1

Studies and epidemiological data suggest that the use of some NSAIDs (especially at high doses and in long-term treatment) may be associated with a small increased risk of vascular thrombotic events (such as myocardial infarction or stroke) (see Precautions section) . Edema, arterial hypertension and heart failure have been observed in the treatment of NSAIDs. Most observed side effects are of gastrointestinal origin. Possible peptic ulcer, perforation or gastrointestinal bleeding, sometimes fatal, especially in elderly patients (see Precautions section). Nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, melena, vomiting of blood, ulcerative stomatitis, exacerbation of colitis and Crohn's disease were observed after use (see section "Precautions"). Gastritis was observed with less frequency. There have been reports of severe skin lesions: Stevens-Johnson syndrome and toxic epidermal necrolysis (see Precautions section). Adverse reactions are presented in accordance with the classification of organ systems and the frequency of occurrence: very often (≥ 1/10), often (≥1/100 to <1/10), infrequently (≥1/1000 to <1/100), rarely ( ≥1/10000 to <1/1000), very rare (<1/10000), not known (cannot be estimated based on available data). From the gastrointestinal tract: very often – digestive system disorders: dyspepsia, nausea, vomiting, abdominal pain, constipation, diarrhea, flatulence; infrequently – latent or macroscopic gastrointestinal bleeding, stomatitis, gastritis, belching; rarely – colitis, gastroduodenal ulcer, esophagitis; very rarely – gastrointestinal perforation. Gastrointestinal bleeding, ulceration, or perforation may be severe or potentially fatal, especially in elderly patients (see Precautions section). Frequency unknown – pancreatitis. From the hepatobiliary system: infrequently – a violation of liver function tests (for example, an increase in transaminases or bilirubin); very rarely – hepatitis; frequency unknown – jaundice, liver failure. On the part of the blood and lymphatic system: infrequently – anemia; rarely – deviation of blood test parameters from the norm (including a change in the number of leukocytes), leukopenia, thrombocytopenia. Cases of agranulocytosis have been reported (see Selected Serious and/or Frequent Adverse Reactions). From the immune system: infrequently – allergic reactions other than anaphylactic or anaphylactoid; frequency unknown – anaphylactic shock, anaphylactic reaction, anaphylactoid reaction, including shock. On the part of the skin and subcutaneous tissue: infrequently – angioedema, itching, rash; rarely – urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis; very rarely – erythema multiforme, bullous dermatitis; frequency unknown – photosensitivity reactions, exfoliative dermatitis. On the part of the respiratory system, chest organs and mediastinum: rarely – asthma in patients allergic to acetylsalicylic acid and other NSAIDs; frequency unknown – respiratory tract infections, cough. On the part of the psyche: rarely – mood changes, nightmares; frequency unknown – confusion, disorientation, insomnia. From the nervous system: often – headache; infrequently – dizziness, drowsiness. From the side of the heart: rarely – a feeling of palpitations. Heart failure associated with the use of NSAIDs has been reported. From the side of the vessels: infrequently – increased blood pressure, hot flashes. From the side of the kidneys and urinary system: infrequently – sodium and water retention, hyperkalemia, changes in kidney function indicators (increased creatinine and / or serum urea); very rarely – acute renal failure, in particular in patients with risk factors; frequency unknown – urinary tract infections, violation of the frequency of urination. On the part of the organs of vision: rarely – conjunctivitis, visual disturbances, including blurred vision. On the part of the hearing organs and the vestibular apparatus: infrequently – dizziness; rarely – ringing in the ears. From the musculoskeletal system and connective tissue: the frequency is unknown – arthralgia, back pain, symptoms associated with the joints. General disorders and reactions at the injection site: often – hardening at the injection site, pain at the injection site; infrequently – edema, including edema of the lower extremities; frequency unknown – flu-like symptoms. Separate serious and / or frequent adverse reactions. Very rare cases of agranulocytosis have been reported in patients taking meloxicam and other potentially myelotoxic drugs (see section "Interaction with other drugs"). Adverse reactions that are not associated with the use of the drug, but which are characteristic of other compounds of the class. Organic renal disease likely leading to acute renal failure: Cases of interstitial nephritis, acute tubular necrosis, nephrotic syndrome, and papillary necrosis have been reported (see Precautions section).